NCT04900454View on ClinicalTrials.gov

Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19

PHASE1CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 1, 2021

Primary Completion Date

June 7, 2022

Study Completion Date

July 1, 2022

Conditions
COVID-19 Pneumonia
Interventions
BIOLOGICAL

DVX201

Single infusion of DVX201, an allogeneic NK cell therapy derived from CD34+ hematopoietic stem cells

Trial Locations (1)

98109

Fred Hutch/University of Washington Medical Center, Seattle

Sponsors
All Listed Sponsors
collaborator

Fred Hutchinson Cancer Center

OTHER

lead

Coeptis Therapeutics

INDUSTRY

NCT04900454 - Allogeneic Natural Killer (NK) Cell Therapy in Subjects Hospitalized for COVID-19 | Biotech Hunter | Biotech Hunter